Simple prognostic score for metastatic castration‐resistant prostate cancer with incorporation of neutrophil‐to‐lymphocyte ratio
暂无分享,去创建一个
I. Tannock | F. Vera-Badillo | J. D. de Bono | G. Attard | E. Amir | A. Omlin | C. Pezaro | M. McNamara | A. Templeton | R. Leibowitz-Amit
[1] Gregory R Pond,et al. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. , 2014, Clinical genitourinary cancer.
[2] Ben Tran,et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.
[3] I. Thompson,et al. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. , 2014, Journal of the National Cancer Institute.
[4] M. Morris,et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] I. Tannock,et al. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] S. Clarke,et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. , 2013, Critical reviews in oncology/hematology.
[7] H. Scher,et al. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] D. McMillan. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. , 2013, Cancer treatment reviews.
[9] I Syndikus,et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.
[10] T. Costantino,et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a€review , 2012 .
[11] M. Carducci,et al. Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. , 2012, The oncologist.
[12] C. Guillemette,et al. Molecular Markers in Key Steroidogenic Pathways, Circulating Steroid Levels, and Prostate Cancer Progression , 2012, Clinical Cancer Research.
[13] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[14] D. McMillan,et al. Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study , 2011, Prostate Cancer and Prostatic Diseases.
[15] G. Pond,et al. Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial. , 2012 .
[16] Ruedi Aebersold,et al. Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome. , 2011, European urology.
[17] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[18] M. Kattan,et al. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. , 2010, European urology.
[19] J. Machiels,et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.
[20] I. Tannock,et al. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. , 2010, European journal of cancer.
[21] K. Pienta,et al. Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.
[22] I. Tannock,et al. A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis , 2007, Clinical Cancer Research.
[23] A. Harris,et al. REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British Journal of Cancer.
[24] P. Kantoff,et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Kevin Regan,et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.